2023 Synapse Cluster Report: Hamilton’s life science sector sees landmark year of growth and global impact
Discover the impressive investments and research advancements in Hamilton’s life sciences ecosystem in the 2023 Synapse Cluster Report.
Ontario Launches Next Phase of Life Sciences Strategy
Discover how the Government of Ontario’s investment of an additional $146 million to boost biomanufacturing will level up their life sciences strategy.
Synapse Consortium Ecosystem Brochure: Connect With Canada’s Leading Health Innovation Ecosystem
Learn more about Synapse Life Science Consortium’s ecosystem brochure that highlights successes, and statistics related to Hamilton’s Health Ecosystem.
Ontario Investing $40 Million in Life Sciences Sector
The Government of Ontario announces a $40 million investment in life sciences at the 2024 Bio International Convention.
McMaster and Kapoose Creek Bio set sights on new fungi-derived medicines in new $2.2M drug discovery partnership
Researchers at Kapoose Creek Bio partner with McMaster University to develop a new synthetic biology platform for fungi-derived medicines.
Made-in-Hamilton app speeds up lifesaving treatment for heart attacks
The Ontario Centre of Innovation recently announced $500,000 in provincial funding to expand a made-in-Hamilton smartphone app into the Ottawa region.
McMaster and the University of Ottawa receive more than $115M to bolster pandemic preparedness in Canada
McMaster and University of Ottawa recieved funding from CBRF to expand Canada’s biomanufacturing industry for development of technology and theraputics.
Success stories inspire the next generation of unicorn founders
Blockbuster AstraZeneca-Fusion Pharmaceuticals announcement shows Hamilton’s life science innovation ecosystem is thriving.
Fusion Pharmaceuticals to be acquired by AstraZeneca, accelerating development of next-generation radioconjugates to treat cancer
Hamilton-based Fusion Pharmaceuticals Inc. has entered into a definitive agreement to be acquired by AstraZeneca.
Fusion Pharmaceuticals Announces IND Clearance For FPI-2068, A Jointly Developed Novel Targeted Alpha Therapy
This press release was originally published by Fusion Pharmaceuticals on April 12, 2023. Read the original post here. FPI-2068 is a Bispecific Targeted Alpha Therapy (TAT) designed to Precisely Deliver Radiation to Tumor Cells HAMILTON, ON and BOSTON, April 12, 2023 /– Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision […]